This is a promotional webinar series; products and brands will be mentioned.

Prescribing information can be found at the bottom of this registration page.

Menopause and HRT Webinar Series

Viatris is delighted to invite you to our free-to-attend live webinar series, hosted by therapy experts on various aspects of the menopause and HRT.

A certificate will be provided on completion of the webinar(s)

Upcoming Webinars

Bleeding on HRT and endometrial protection

7th November 2023, 7-8pm

Mr Vikram Talaulikar & Dr Katie Barber

Learning Outcomes

  • To provide an overview of latest market developments and clinical update
  • To provide an insight into ensuring patient compliance to progestogen and endometrial protection from a primary care’s point of view
  • To provide an understanding on managing the two-week wait process from a secondary care’s perspective
  • To provide practical tips on managing break through or unscheduled bleeding for patients on HRT

Women’s Health in Primary Care:

Part I: Navigating recurrent UTIs during the menopause
Part II: Managing menopause and HRT

30th January 2024, 7-8pm

Dr Diana Mansour & Dr Cat Anderson

Learning Outcomes

  • Addressing management and treatment of rUTIs in primary care
  • Reviewing common menopausal patient case studies and treatment
  • Managing the HRT minefield, which route, progestogen and why?

A certificate will be provided on completion of the webinar(s)

Registration

Free for UK healthcare professionals

Click on the logos below to access the prescribing information

Elleste® Duet and Solo are indicated for oestrogen deficiency symptoms in post- and peri-menopausal women and Ellest® duet Conti is indicated indicated for the oestrogen deficiency symptoms in women one year since last menses.

Femoston® is indicated for oestrogen deficiency symptoms in postmenopausal women at least 6 months since last menses.

Femoston®-conti is indicated for oestrogen deficiency symptoms in postmenopausal women at least 12 months since last menses.

Zumenon® is indicated for oestrogen deficiency symptoms in postmenopausal women at least 6 months since last menses.

Reporting of side effects:
If you get any side effects or have a device failure, talk to your doctor, pharmacist or nurse. This includes any possible side effects not listed in the package leaflet. Please report side effects or device failures with any medicine or vaccine to the medicines regulator MHRA through the Yellow Card Scheme. It is easiest and quickest to report side effects and device failures online via the Yellow Card website: https://yellowcard.mhra.gov.uk/ or search for MHRA Yellow Card in the Google Play or Apple App Store.

Alternatively, prepaid Yellow Cards for reporting are available by writing to FREEPOST YELLOW CARD (no other address details necessary), by emailing yellowcard@mhra.gov.uk, by telephoning the Commission on Human Medicines (CHM) free phone line: 0800-731-6789, or by downloading and printing a form from the Yellow Card section of the MHRA website. You can also report side effects and device failures direct to the marketing authorisation holder at pv.uk@viatris.com.

©2023 – All rights reserved. Viatris UK Healthcare Limited, a company incorporated in England and Wales with Company Number 09189103, Vat Number: GB 421 623 781 and having its registered office at Station Close Potters Bar, Hert, EN6 1TL.

FEM-2023-0209    |  October 2023

Website designed by E4H